Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohns disease and ulcerative colitis-experiences from a single center

Expert Opinion on Biological Therapy

Volumn 15, Issue 9, 2015, Pages 1257-1262

  Farkas, Klaudia ^a   Rutka, Mariann ^a   Bálint, Anita ^a   Nagy, Ferenc ^a   Bor, Renáta ^a   Milassin, Ágnes ^a   Szepes, Zoltán ^a   Molnár, Tamás ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Crohn's disease; CT P13; efficacy; infliximab biosimilar; ulcerative colitis

Indexed keywords

CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; BIOSIMILAR AGENT; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; CHILD; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALING; HUMAN; INDUCTION CHEMOTHERAPY; MALE; PYODERMA GANGRENOSUM; REMISSION; SIGMOIDOSCOPY; TOXIC MEGACOLON; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGED; CHEMISTRY; COLITIS, ULCERATIVE; COLONOSCOPY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; COLONOSCOPY; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938821686     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1064893     Document Type: Article

References (17)

1. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72 (10): 1613-20
2. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72 (10): 1605-12
3. Kang YS, Moon HH, Lee SE, et al. Clinical Experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: A Case Series. Dig Dis Sci 2014
4. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohns disease activity index. National Cooperative Crohns Disease Study. Gastroenterology 1976; 70 (3): 439-44
5. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317 (26): 1625-9
6. Irvine EJ. Usual therapy improves perianal Crohns disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20 (1): 27-32
7. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med 1999; 340 (18): 1398-405
8. Online G. Generics and Biosimilars Initiative. Efficacy, extrapolation and interchangeability of biosimilars. 2014. Available from: www.gabionline.net/Biosimilars/Research/Efficacy-extrapolation-and interchangeability-of-biosimilars. [Last accessed 01 June 2015]
9. Online G. Generics and Biosimilars Initiative. Extrapolation of biosimilar infliximab indications to inflammatory bowel disease. 2014. Available from: www.gabionline.net/Biosimilars/Research/Extrapolation-of-biosimilar-infliximab-indications-to-inflammatory-bowel-disease. [Last accessed 01 June 2015]
10. Online G. Generics and Biosimilars Initiative. ABPI issues updated position paper on biosimilars. 2014. Available from: www.gabionline.net/Biosimilars/General/ABPI-issues-updated-position-paper-on-biosimilars. [Last accessed 01 June 2015]
11. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53 (10): 1471-8
12. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131 (3): 719-28
13. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014; 63 (1): 72-9
14. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 (Suppl 1): S65-71
15. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7 (7): 586-9
16. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs 2014; 28 (3): 313-21
17. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohns and Colitis Organization. J Crohns Colitis 2014; 8 (11): 1548-50